Titre : Glycoprotéines membranaires

Glycoprotéines membranaires : Questions médicales fréquentes

Termes MeSH sélectionnés :

Transcranial Direct Current Stimulation

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une anomalie des glycoprotéines membranaires ?

Des tests sanguins et des biopsies peuvent révéler des anomalies glycoprotéiques.
Glycoprotéines Biopsie Tests sanguins
#2

Quels tests sont utilisés pour évaluer les glycoprotéines ?

L'électrophorèse et la chromatographie sont couramment utilisés pour l'évaluation.
Électrophorèse Chromatographie Glycoprotéines
#3

Les tests génétiques sont-ils utiles pour les glycoprotéines ?

Oui, les tests génétiques peuvent identifier des mutations affectant les glycoprotéines.
Tests génétiques Glycoprotéines Mutations
#4

Quels marqueurs sont associés aux glycoprotéines ?

Des marqueurs comme les antigènes peuvent indiquer des anomalies glycoprotéiques.
Antigènes Glycoprotéines Marqueurs biologiques
#5

Les imageries médicales aident-elles au diagnostic ?

Certaines imageries peuvent montrer des changements cellulaires liés aux glycoprotéines.
Imagerie médicale Glycoprotéines Changements cellulaires

Symptômes 5

#1

Quels symptômes indiquent un problème de glycoprotéines ?

Des symptômes comme l'inflammation ou des troubles immunitaires peuvent survenir.
Inflammation Troubles immunitaires Glycoprotéines
#2

Les troubles neurologiques sont-ils liés aux glycoprotéines ?

Oui, certaines glycoprotéines sont impliquées dans des maladies neurologiques.
Troubles neurologiques Glycoprotéines Maladies neurodégénératives
#3

Peut-on observer des symptômes cutanés ?

Des éruptions cutanées peuvent être liées à des anomalies des glycoprotéines.
Éruptions cutanées Glycoprotéines Dermatologie
#4

Les troubles respiratoires sont-ils associés aux glycoprotéines ?

Certaines glycoprotéines peuvent affecter la fonction pulmonaire et causer des troubles.
Troubles respiratoires Glycoprotéines Fonction pulmonaire
#5

Les symptômes digestifs peuvent-ils être liés ?

Oui, des anomalies glycoprotéiques peuvent entraîner des troubles digestifs.
Symptômes digestifs Glycoprotéines Troubles gastro-intestinaux

Prévention 5

#1

Comment prévenir les troubles liés aux glycoprotéines ?

Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir ces troubles.
Prévention Glycoprotéines Mode de vie sain
#2

Les vaccinations sont-elles importantes ?

Oui, certaines vaccinations peuvent prévenir des infections affectant les glycoprotéines.
Vaccinations Glycoprotéines Infections
#3

Le dépistage précoce est-il recommandé ?

Oui, le dépistage peut aider à identifier les anomalies glycoprotéiques tôt.
Dépistage Glycoprotéines Prévention
#4

Les habitudes de vie influencent-elles la santé des glycoprotéines ?

Oui, des habitudes saines peuvent améliorer la santé cellulaire et glycoprotéique.
Habitudes de vie Glycoprotéines Santé cellulaire
#5

L'éducation à la santé est-elle cruciale ?

Oui, sensibiliser à la santé peut aider à prévenir les troubles liés aux glycoprotéines.
Éducation à la santé Glycoprotéines Prévention

Traitements 5

#1

Quels traitements ciblent les anomalies glycoprotéiques ?

Des thérapies géniques et des médicaments immunomodulateurs peuvent être utilisés.
Thérapie génique Médicaments immunomodulateurs Glycoprotéines
#2

Les traitements biologiques sont-ils efficaces ?

Oui, les traitements biologiques peuvent cibler spécifiquement les glycoprotéines.
Traitements biologiques Glycoprotéines Immunothérapie
#3

La nutrition joue-t-elle un rôle dans le traitement ?

Une alimentation riche en nutriments peut soutenir la fonction des glycoprotéines.
Nutrition Glycoprotéines Fonction cellulaire
#4

Les thérapies physiques sont-elles bénéfiques ?

Oui, elles peuvent aider à améliorer la fonction cellulaire et réduire les symptômes.
Thérapies physiques Glycoprotéines Réhabilitation
#5

Les médicaments anti-inflammatoires sont-ils utilisés ?

Oui, ils peuvent réduire l'inflammation liée aux anomalies glycoprotéiques.
Médicaments anti-inflammatoires Glycoprotéines Inflammation

Complications 5

#1

Quelles complications peuvent survenir avec des anomalies glycoprotéiques ?

Des complications comme des maladies auto-immunes ou des cancers peuvent survenir.
Complications Glycoprotéines Maladies auto-immunes
#2

Les complications neurologiques sont-elles fréquentes ?

Oui, des troubles neurologiques peuvent être des complications des anomalies glycoprotéiques.
Complications neurologiques Glycoprotéines Troubles neurologiques
#3

Les complications cardiovasculaires sont-elles possibles ?

Certaines anomalies glycoprotéiques peuvent augmenter le risque de maladies cardiovasculaires.
Complications cardiovasculaires Glycoprotéines Maladies cardiovasculaires
#4

Les complications infectieuses sont-elles liées ?

Oui, des anomalies glycoprotéiques peuvent rendre les cellules plus vulnérables aux infections.
Complications infectieuses Glycoprotéines Infections
#5

Les complications métaboliques sont-elles possibles ?

Certaines anomalies glycoprotéiques peuvent entraîner des troubles métaboliques.
Complications métaboliques Glycoprotéines Troubles métaboliques

Facteurs de risque 5

#1

Quels facteurs de risque sont associés aux anomalies glycoprotéiques ?

Des facteurs comme l'âge, la génétique et l'environnement peuvent influencer les anomalies.
Facteurs de risque Glycoprotéines Génétique
#2

Le mode de vie influence-t-il les glycoprotéines ?

Oui, un mode de vie malsain peut augmenter le risque d'anomalies glycoprotéiques.
Mode de vie Glycoprotéines Santé
#3

Les maladies chroniques sont-elles un facteur de risque ?

Oui, des maladies chroniques peuvent prédisposer à des anomalies glycoprotéiques.
Maladies chroniques Glycoprotéines Prédisposition
#4

L'exposition à des toxines est-elle un risque ?

Oui, l'exposition à certaines toxines peut affecter la structure des glycoprotéines.
Exposition à des toxines Glycoprotéines Toxines
#5

Le stress a-t-il un impact sur les glycoprotéines ?

Oui, le stress chronique peut influencer la fonction des glycoprotéines et la santé cellulaire.
Stress Glycoprotéines Santé cellulaire
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Glycoprotéines membranaires : Questions médicales les plus fréquentes", "headline": "Glycoprotéines membranaires : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Glycoprotéines membranaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-03", "dateModified": "2025-03-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Glycoprotéines membranaires" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines membranaires", "url": "https://questionsmedicales.fr/mesh/D008565", "about": { "@type": "MedicalCondition", "name": "Protéines membranaires", "code": { "@type": "MedicalCode", "code": "D008565", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Antigène AC133", "alternateName": "AC133 Antigen", "url": "https://questionsmedicales.fr/mesh/D000071916", "about": { "@type": "MedicalCondition", "name": "Antigène AC133", "code": { "@type": "MedicalCode", "code": "D000071916", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.023" } } }, { "@type": "MedicalWebPage", "name": "Antigènes CD38", "alternateName": "ADP-ribosyl Cyclase 1", "url": "https://questionsmedicales.fr/mesh/D051997", "about": { "@type": "MedicalCondition", "name": "Antigènes CD38", "code": { "@type": "MedicalCode", "code": "D051997", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.045" } } }, { "@type": "MedicalWebPage", "name": "Antigènes CD47", "alternateName": "CD47 Antigen", "url": "https://questionsmedicales.fr/mesh/D051928", "about": { "@type": "MedicalCondition", "name": "Antigènes CD47", "code": { "@type": "MedicalCode", "code": "D051928", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.147" } } }, { "@type": "MedicalWebPage", "name": "Antigènes CD58", "alternateName": "CD58 Antigens", "url": "https://questionsmedicales.fr/mesh/D018968", "about": { "@type": "MedicalCondition", "name": "Antigènes CD58", "code": { "@type": "MedicalCode", "code": "D018968", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.158" } } }, { "@type": "MedicalWebPage", "name": "Butyrophilines", "alternateName": "Butyrophilins", "url": "https://questionsmedicales.fr/mesh/D000071797", "about": { "@type": "MedicalCondition", "name": "Butyrophilines", "code": { "@type": "MedicalCode", "code": "D000071797", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.195" } } }, { "@type": "MedicalWebPage", "name": "Protéines liées au GPI", "alternateName": "GPI-Linked Proteins", "url": "https://questionsmedicales.fr/mesh/D058851", "about": { "@type": "MedicalCondition", "name": "Protéines liées au GPI", "code": { "@type": "MedicalCode", "code": "D058851", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.418" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Antigènes CD55", "alternateName": "CD55 Antigens", "url": "https://questionsmedicales.fr/mesh/D018958", "about": { "@type": "MedicalCondition", "name": "Antigènes CD55", "code": { "@type": "MedicalCode", "code": "D018958", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.418.130" } } }, { "@type": "MedicalWebPage", "name": "Antigènes CD59", "alternateName": "CD59 Antigens", "url": "https://questionsmedicales.fr/mesh/D018957", "about": { "@type": "MedicalCondition", "name": "Antigènes CD59", "code": { "@type": "MedicalCode", "code": "D018957", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.418.140" } } }, { "@type": "MedicalWebPage", "name": "Antigène stromal-2 de la moëlle osseuse", "alternateName": "Bone Marrow Stromal Antigen 2", "url": "https://questionsmedicales.fr/mesh/D000074010", "about": { "@type": "MedicalCondition", "name": "Antigène stromal-2 de la moëlle osseuse", "code": { "@type": "MedicalCode", "code": "D000074010", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.418.150" } } }, { "@type": "MedicalWebPage", "name": "Carbonic anhydrase-IV", "alternateName": "Carbonic Anhydrase IV", "url": "https://questionsmedicales.fr/mesh/D030741", "about": { "@type": "MedicalCondition", "name": "Carbonic anhydrase-IV", "code": { "@type": "MedicalCode", "code": "D030741", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.418.160" } } }, { "@type": "MedicalWebPage", "name": "Glypicanes", "alternateName": "Glypicans", "url": "https://questionsmedicales.fr/mesh/D053673", "about": { "@type": "MedicalCondition", "name": "Glypicanes", "code": { "@type": "MedicalCode", "code": "D053673", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.418.500" } } }, { "@type": "MedicalWebPage", "name": "Matrix metalloproteinase 17", "alternateName": "Matrix Metalloproteinase 17", "url": "https://questionsmedicales.fr/mesh/D053515", "about": { "@type": "MedicalCondition", "name": "Matrix metalloproteinase 17", "code": { "@type": "MedicalCode", "code": "D053515", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.418.700" } } }, { "@type": "MedicalWebPage", "name": "Uromoduline", "alternateName": "Uromodulin", "url": "https://questionsmedicales.fr/mesh/D058949", "about": { "@type": "MedicalCondition", "name": "Uromoduline", "code": { "@type": "MedicalCode", "code": "D058949", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.418.850" } } } ] }, { "@type": "MedicalWebPage", "name": "Glycoprotéines de membrane associées au lysosome", "alternateName": "Lysosome-Associated Membrane Glycoproteins", "url": "https://questionsmedicales.fr/mesh/D051907", "about": { "@type": "MedicalCondition", "name": "Glycoprotéines de membrane associées au lysosome", "code": { "@type": "MedicalCode", "code": "D051907", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.527" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Protéine de membrane-2 associée au lysosome", "alternateName": "Lysosomal-Associated Membrane Protein 2", "url": "https://questionsmedicales.fr/mesh/D052119", "about": { "@type": "MedicalCondition", "name": "Protéine de membrane-2 associée au lysosome", "code": { "@type": "MedicalCode", "code": "D052119", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.527.750" } } }, { "@type": "MedicalWebPage", "name": "Protéine-3 de membrane associée au lysosome", "alternateName": "Lysosomal-Associated Membrane Protein 3", "url": "https://questionsmedicales.fr/mesh/D059666", "about": { "@type": "MedicalCondition", "name": "Protéine-3 de membrane associée au lysosome", "code": { "@type": "MedicalCode", "code": "D059666", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.527.875" } } } ] }, { "@type": "MedicalWebPage", "name": "Mucine-3", "alternateName": "Mucin-3", "url": "https://questionsmedicales.fr/mesh/D055263", "about": { "@type": "MedicalCondition", "name": "Mucine-3", "code": { "@type": "MedicalCode", "code": "D055263", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.542" } } }, { "@type": "MedicalWebPage", "name": "PHEX Phosphate regulating neutral endopeptidase", "alternateName": "PHEX Phosphate Regulating Neutral Endopeptidase", "url": "https://questionsmedicales.fr/mesh/D053402", "about": { "@type": "MedicalCondition", "name": "PHEX Phosphate regulating neutral endopeptidase", "code": { "@type": "MedicalCode", "code": "D053402", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.607" } } }, { "@type": "MedicalWebPage", "name": "Sarcoglycanes", "alternateName": "Sarcoglycans", "url": "https://questionsmedicales.fr/mesh/D049031", "about": { "@type": "MedicalCondition", "name": "Sarcoglycanes", "code": { "@type": "MedicalCode", "code": "D049031", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.712" } } }, { "@type": "MedicalWebPage", "name": "Syndécanes", "alternateName": "Syndecans", "url": "https://questionsmedicales.fr/mesh/D053667", "about": { "@type": "MedicalCondition", "name": "Syndécanes", "code": { "@type": "MedicalCode", "code": "D053667", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.847" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Syndécane-1", "alternateName": "Syndecan-1", "url": "https://questionsmedicales.fr/mesh/D053668", "about": { "@type": "MedicalCondition", "name": "Syndécane-1", "code": { "@type": "MedicalCode", "code": "D053668", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.847.100" } } }, { "@type": "MedicalWebPage", "name": "Syndécane-2", "alternateName": "Syndecan-2", "url": "https://questionsmedicales.fr/mesh/D053669", "about": { "@type": "MedicalCondition", "name": "Syndécane-2", "code": { "@type": "MedicalCode", "code": "D053669", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.847.200" } } }, { "@type": "MedicalWebPage", "name": "Syndécane-3", "alternateName": "Syndecan-3", "url": "https://questionsmedicales.fr/mesh/D053670", "about": { "@type": "MedicalCondition", "name": "Syndécane-3", "code": { "@type": "MedicalCode", "code": "D053670", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.847.300" } } }, { "@type": "MedicalWebPage", "name": "Syndécane-4", "alternateName": "Syndecan-4", "url": "https://questionsmedicales.fr/mesh/D053671", "about": { "@type": "MedicalCondition", "name": "Syndécane-4", "code": { "@type": "MedicalCode", "code": "D053671", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.847.400" } } } ] }, { "@type": "MedicalWebPage", "name": "Thrombospondines", "alternateName": "Thrombospondins", "url": "https://questionsmedicales.fr/mesh/D019699", "about": { "@type": "MedicalCondition", "name": "Thrombospondines", "code": { "@type": "MedicalCode", "code": "D019699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.895" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Thrombospondine-1", "alternateName": "Thrombospondin 1", "url": "https://questionsmedicales.fr/mesh/D019700", "about": { "@type": "MedicalCondition", "name": "Thrombospondine-1", "code": { "@type": "MedicalCode", "code": "D019700", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.895.800" } } } ] }, { "@type": "MedicalWebPage", "name": "Uroplakines", "alternateName": "Uroplakins", "url": "https://questionsmedicales.fr/mesh/D060165", "about": { "@type": "MedicalCondition", "name": "Uroplakines", "code": { "@type": "MedicalCode", "code": "D060165", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.942" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Uroplakine II", "alternateName": "Uroplakin II", "url": "https://questionsmedicales.fr/mesh/D060170", "about": { "@type": "MedicalCondition", "name": "Uroplakine II", "code": { "@type": "MedicalCode", "code": "D060170", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.942.200" } } }, { "@type": "MedicalWebPage", "name": "Uroplakine III", "alternateName": "Uroplakin III", "url": "https://questionsmedicales.fr/mesh/D060171", "about": { "@type": "MedicalCondition", "name": "Uroplakine III", "code": { "@type": "MedicalCode", "code": "D060171", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.942.300" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Glycoprotéines membranaires", "alternateName": "Membrane Glycoproteins", "code": { "@type": "MedicalCode", "code": "D008562", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Yang Liu", "url": "https://questionsmedicales.fr/author/Yang%20Liu", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430207, China." } }, { "@type": "Person", "name": "Hanh T Nguyen", "url": "https://questionsmedicales.fr/author/Hanh%20T%20Nguyen", "affiliation": { "@type": "Organization", "name": "Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA." } }, { "@type": "Person", "name": "Pablo Guardado-Calvo", "url": "https://questionsmedicales.fr/author/Pablo%20Guardado-Calvo", "affiliation": { "@type": "Organization", "name": "Structural Virology Unit, Institut Pasteur - Université Paris-Cité, CNRS UMR 3569, 25-28 rue du Dr. Roux, 75015 Paris, France." } }, { "@type": "Person", "name": "Félix A Rey", "url": "https://questionsmedicales.fr/author/F%C3%A9lix%20A%20Rey", "affiliation": { "@type": "Organization", "name": "Structural Virology Unit, Institut Pasteur - Université Paris-Cité, CNRS UMR 3569, 25-28 rue du Dr. Roux, 75015 Paris, France. Electronic address: felix.rey@pasteur.fr." } }, { "@type": "Person", "name": "Cheng Man Lun", "url": "https://questionsmedicales.fr/author/Cheng%20Man%20Lun", "affiliation": { "@type": "Organization", "name": "Virus-Cell Interaction Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Cingulate transcranial direct current stimulation in adults with HIV.", "datePublished": "2022-06-03", "url": "https://questionsmedicales.fr/article/35658059", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0269491" } }, { "@type": "ScholarlyArticle", "name": "Noninvasive Brain Stimulation Techniques for Treatment-Resistant Depression: Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation.", "datePublished": "2023-03-15", "url": "https://questionsmedicales.fr/article/37149347", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.psc.2023.02.005" } }, { "@type": "ScholarlyArticle", "name": "Targeting the insula with transcranial direct current stimulation; A simulation study.", "datePublished": "2023-09-15", "url": "https://questionsmedicales.fr/article/37738706", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.pscychresns.2023.111718" } }, { "@type": "ScholarlyArticle", "name": "Transcranial magnetic stimulation and transcranial direct current stimulation affect explicit but not implicit emotion regulation: a meta-analysis.", "datePublished": "2023-09-19", "url": "https://questionsmedicales.fr/article/37726856", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12993-023-00217-8" } }, { "@type": "ScholarlyArticle", "name": "Novel ways to modulate the vestibular system: Magnetic vestibular stimulation, deep brain stimulation and transcranial magnetic stimulation / transcranial direct current stimulation.", "datePublished": "2023-01-04", "url": "https://questionsmedicales.fr/article/36621040", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jns.2023.120544" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Glycoprotéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008562" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Glycoprotéines membranaires - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Glycoprotéines membranaires", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Glycoprotéines membranaires", "description": "Comment diagnostiquer une anomalie des glycoprotéines membranaires ?\nQuels tests sont utilisés pour évaluer les glycoprotéines ?\nLes tests génétiques sont-ils utiles pour les glycoprotéines ?\nQuels marqueurs sont associés aux glycoprotéines ?\nLes imageries médicales aident-elles au diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D008562?mesh_terms=Transcranial+Direct+Current+Stimulation#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Glycoprotéines membranaires", "description": "Quels symptômes indiquent un problème de glycoprotéines ?\nLes troubles neurologiques sont-ils liés aux glycoprotéines ?\nPeut-on observer des symptômes cutanés ?\nLes troubles respiratoires sont-ils associés aux glycoprotéines ?\nLes symptômes digestifs peuvent-ils être liés ?", "url": "https://questionsmedicales.fr/mesh/D008562?mesh_terms=Transcranial+Direct+Current+Stimulation#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Glycoprotéines membranaires", "description": "Comment prévenir les troubles liés aux glycoprotéines ?\nLes vaccinations sont-elles importantes ?\nLe dépistage précoce est-il recommandé ?\nLes habitudes de vie influencent-elles la santé des glycoprotéines ?\nL'éducation à la santé est-elle cruciale ?", "url": "https://questionsmedicales.fr/mesh/D008562?mesh_terms=Transcranial+Direct+Current+Stimulation#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Glycoprotéines membranaires", "description": "Quels traitements ciblent les anomalies glycoprotéiques ?\nLes traitements biologiques sont-ils efficaces ?\nLa nutrition joue-t-elle un rôle dans le traitement ?\nLes thérapies physiques sont-elles bénéfiques ?\nLes médicaments anti-inflammatoires sont-ils utilisés ?", "url": "https://questionsmedicales.fr/mesh/D008562?mesh_terms=Transcranial+Direct+Current+Stimulation#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Glycoprotéines membranaires", "description": "Quelles complications peuvent survenir avec des anomalies glycoprotéiques ?\nLes complications neurologiques sont-elles fréquentes ?\nLes complications cardiovasculaires sont-elles possibles ?\nLes complications infectieuses sont-elles liées ?\nLes complications métaboliques sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D008562?mesh_terms=Transcranial+Direct+Current+Stimulation#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Glycoprotéines membranaires", "description": "Quels facteurs de risque sont associés aux anomalies glycoprotéiques ?\nLe mode de vie influence-t-il les glycoprotéines ?\nLes maladies chroniques sont-elles un facteur de risque ?\nL'exposition à des toxines est-elle un risque ?\nLe stress a-t-il un impact sur les glycoprotéines ?", "url": "https://questionsmedicales.fr/mesh/D008562?mesh_terms=Transcranial+Direct+Current+Stimulation#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des glycoprotéines membranaires ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies peuvent révéler des anomalies glycoprotéiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les glycoprotéines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'électrophorèse et la chromatographie sont couramment utilisés pour l'évaluation." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour les glycoprotéines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier des mutations affectant les glycoprotéines." } }, { "@type": "Question", "name": "Quels marqueurs sont associés aux glycoprotéines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme les antigènes peuvent indiquer des anomalies glycoprotéiques." } }, { "@type": "Question", "name": "Les imageries médicales aident-elles au diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Certaines imageries peuvent montrer des changements cellulaires liés aux glycoprotéines." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème de glycoprotéines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme l'inflammation ou des troubles immunitaires peuvent survenir." } }, { "@type": "Question", "name": "Les troubles neurologiques sont-ils liés aux glycoprotéines ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines glycoprotéines sont impliquées dans des maladies neurologiques." } }, { "@type": "Question", "name": "Peut-on observer des symptômes cutanés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées peuvent être liées à des anomalies des glycoprotéines." } }, { "@type": "Question", "name": "Les troubles respiratoires sont-ils associés aux glycoprotéines ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Certaines glycoprotéines peuvent affecter la fonction pulmonaire et causer des troubles." } }, { "@type": "Question", "name": "Les symptômes digestifs peuvent-ils être liés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies glycoprotéiques peuvent entraîner des troubles digestifs." } }, { "@type": "Question", "name": "Comment prévenir les troubles liés aux glycoprotéines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir ces troubles." } }, { "@type": "Question", "name": "Les vaccinations sont-elles importantes ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines vaccinations peuvent prévenir des infections affectant les glycoprotéines." } }, { "@type": "Question", "name": "Le dépistage précoce est-il recommandé ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage peut aider à identifier les anomalies glycoprotéiques tôt." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles la santé des glycoprotéines ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes saines peuvent améliorer la santé cellulaire et glycoprotéique." } }, { "@type": "Question", "name": "L'éducation à la santé est-elle cruciale ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sensibiliser à la santé peut aider à prévenir les troubles liés aux glycoprotéines." } }, { "@type": "Question", "name": "Quels traitements ciblent les anomalies glycoprotéiques ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des médicaments immunomodulateurs peuvent être utilisés." } }, { "@type": "Question", "name": "Les traitements biologiques sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements biologiques peuvent cibler spécifiquement les glycoprotéines." } }, { "@type": "Question", "name": "La nutrition joue-t-elle un rôle dans le traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en nutriments peut soutenir la fonction des glycoprotéines." } }, { "@type": "Question", "name": "Les thérapies physiques sont-elles bénéfiques ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent aider à améliorer la fonction cellulaire et réduire les symptômes." } }, { "@type": "Question", "name": "Les médicaments anti-inflammatoires sont-ils utilisés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent réduire l'inflammation liée aux anomalies glycoprotéiques." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des anomalies glycoprotéiques ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des maladies auto-immunes ou des cancers peuvent survenir." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles fréquentes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles neurologiques peuvent être des complications des anomalies glycoprotéiques." } }, { "@type": "Question", "name": "Les complications cardiovasculaires sont-elles possibles ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines anomalies glycoprotéiques peuvent augmenter le risque de maladies cardiovasculaires." } }, { "@type": "Question", "name": "Les complications infectieuses sont-elles liées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies glycoprotéiques peuvent rendre les cellules plus vulnérables aux infections." } }, { "@type": "Question", "name": "Les complications métaboliques sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines anomalies glycoprotéiques peuvent entraîner des troubles métaboliques." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés aux anomalies glycoprotéiques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'âge, la génétique et l'environnement peuvent influencer les anomalies." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il les glycoprotéines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut augmenter le risque d'anomalies glycoprotéiques." } }, { "@type": "Question", "name": "Les maladies chroniques sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies chroniques peuvent prédisposer à des anomalies glycoprotéiques." } }, { "@type": "Question", "name": "L'exposition à des toxines est-elle un risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certaines toxines peut affecter la structure des glycoprotéines." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur les glycoprotéines ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut influencer la fonction des glycoprotéines et la santé cellulaire." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 30/03/2025

Contenu vérifié selon les dernières recommandations médicales

Sous-catégories

29 au total
└─

Antigène AC133

AC133 Antigen D000071916 - D12.776.543.550.023
└─

Antigènes CD38

ADP-ribosyl Cyclase 1 D051997 - D12.776.543.550.045
└─

Antigènes CD47

CD47 Antigen D051928 - D12.776.543.550.147
└─

Antigènes CD58

CD58 Antigens D018968 - D12.776.543.550.158
└─

Butyrophilines

Butyrophilins D000071797 - D12.776.543.550.195
└─

Protéines liées au GPI

GPI-Linked Proteins D058851 - D12.776.543.550.418
└─

Glycoprotéines de membrane associées au lysosome

Lysosome-Associated Membrane Glycoproteins D051907 - D12.776.543.550.527
└─

Mucine-3

Mucin-3 D055263 - D12.776.543.550.542
└─

PHEX Phosphate regulating neutral endopeptidase

PHEX Phosphate Regulating Neutral Endopeptidase D053402 - D12.776.543.550.607
└─

Sarcoglycanes

Sarcoglycans D049031 - D12.776.543.550.712
└─

Syndécanes

Syndecans D053667 - D12.776.543.550.847
└─

Thrombospondines

Thrombospondins D019699 - D12.776.543.550.895
└─

Uroplakines

Uroplakins D060165 - D12.776.543.550.942
└─└─

Antigènes CD55

CD55 Antigens D018958 - D12.776.543.550.418.130
└─└─

Antigènes CD59

CD59 Antigens D018957 - D12.776.543.550.418.140
└─└─

Antigène stromal-2 de la moëlle osseuse

Bone Marrow Stromal Antigen 2 D000074010 - D12.776.543.550.418.150
└─└─

Carbonic anhydrase-IV

Carbonic Anhydrase IV D030741 - D12.776.543.550.418.160
└─└─

Glypicanes

Glypicans D053673 - D12.776.543.550.418.500
└─└─

Matrix metalloproteinase 17

Matrix Metalloproteinase 17 D053515 - D12.776.543.550.418.700
└─└─

Uromoduline

Uromodulin D058949 - D12.776.543.550.418.850
└─└─

Protéine de membrane-2 associée au lysosome

Lysosomal-Associated Membrane Protein 2 D052119 - D12.776.543.550.527.750
└─└─

Protéine-3 de membrane associée au lysosome

Lysosomal-Associated Membrane Protein 3 D059666 - D12.776.543.550.527.875
└─└─

Syndécane-1

Syndecan-1 D053668 - D12.776.543.550.847.100
└─└─

Syndécane-2

Syndecan-2 D053669 - D12.776.543.550.847.200
└─└─

Syndécane-3

Syndecan-3 D053670 - D12.776.543.550.847.300
└─└─

Syndécane-4

Syndecan-4 D053671 - D12.776.543.550.847.400
└─└─

Thrombospondine-1

Thrombospondin 1 D019700 - D12.776.543.550.895.800
└─└─

Uroplakine II

Uroplakin II D060170 - D12.776.543.550.942.200
└─└─

Uroplakine III

Uroplakin III D060171 - D12.776.543.550.942.300

Auteurs principaux

Yang Liu

4 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430207, China.

Hanh T Nguyen

3 publications dans cette catégorie

Affiliations :
  • Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA.

Pablo Guardado-Calvo

2 publications dans cette catégorie

Affiliations :
  • Structural Virology Unit, Institut Pasteur - Université Paris-Cité, CNRS UMR 3569, 25-28 rue du Dr. Roux, 75015 Paris, France.
Publications dans "Glycoprotéines membranaires" :

Félix A Rey

2 publications dans cette catégorie

Affiliations :
  • Structural Virology Unit, Institut Pasteur - Université Paris-Cité, CNRS UMR 3569, 25-28 rue du Dr. Roux, 75015 Paris, France. Electronic address: felix.rey@pasteur.fr.
Publications dans "Glycoprotéines membranaires" :

Cheng Man Lun

2 publications dans cette catégorie

Affiliations :
  • Virus-Cell Interaction Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
Publications dans "Glycoprotéines membranaires" :

Abdul A Waheed

2 publications dans cette catégorie

Affiliations :
  • Virus-Cell Interaction Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
Publications dans "Glycoprotéines membranaires" :

Nicole Powell

2 publications dans cette catégorie

Affiliations :
  • Virus-Cell Interaction Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.
Publications dans "Glycoprotéines membranaires" :

Eric O Freed

2 publications dans cette catégorie

Affiliations :
  • Virus-Cell Interaction Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USA efreed@nih.gov.
Publications dans "Glycoprotéines membranaires" :

Emad Tajkhorshid

2 publications dans cette catégorie

Affiliations :
  • NIH Center for Macromolecular Modeling and Bioinformatics, Beckman Institute for Advanced Science and Technology, Department of Biochemistry, Center for Biophysics and Quantitative Biology, University of Illinois at Urbana-Champaign Urbana IL 61801 USA emad@illinois.edu.
Publications dans "Glycoprotéines membranaires" :

James B Munro

2 publications dans cette catégorie

Affiliations :
  • Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, United States.
  • Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, United States.

Minmin Zhou

2 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430207, China; University of the Chinese Academy of Sciences, Beijing, 100049, China.

Gengfu Xiao

2 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430207, China; University of the Chinese Academy of Sciences, Beijing, 100049, China.

Wei Wang

2 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430207, China; University of the Chinese Academy of Sciences, Beijing, 100049, China. Electronic address: wangwei@wh.iov.cn.

Xiyang Zhang

2 publications dans cette catégorie

Affiliations :
  • Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, 86-710032, PR China.

Yuanjie Sun

2 publications dans cette catégorie

Affiliations :
  • Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, 86-710032, PR China.

Shuya Yang

2 publications dans cette catégorie

Affiliations :
  • Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, 86-710032, PR China.

Dongbo Jiang

2 publications dans cette catégorie

Affiliations :
  • Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, 86-710032, PR China. Electronic address: superjames1991@foxmail.com.

Kun Yang

2 publications dans cette catégorie

Affiliations :
  • Department of Immunology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an, Shaanxi, 86-710032, PR China. Electronic address: yangkunkun@fmmu.edu.cn.

Yue Liu

2 publications dans cette catégorie

Affiliations :
  • School of Pharmacy, Naval Medical University, 325 Guohe Road, Shanghai 200433, China.

Yan Cao

2 publications dans cette catégorie

Affiliations :
  • School of Pharmacy, Naval Medical University, 325 Guohe Road, Shanghai 200433, China.

Sources (10000 au total)

Cingulate transcranial direct current stimulation in adults with HIV.

Neuronal dysfunction plays an important role in the high prevalence of HIV-associated neurocognitive disorders (HAND) in people with HIV (PWH). Transcranial direct current stimulation (tDCS)-with its ... Eleven PWH (47-69 years old, 2 females, 100% African Americans, disease duration 16-36 years) participated in the study, which had two phases, Phase 1 and Phase 2. During Phase 1, participants were ra... Compared to sham tDCS, cingulate tDCS led to a decrease in Perseverative Errors in Wisconsin Card Sorting Test (WCST), but not Non-Perseverative Errors, as well as a decrease in the ratio score of Tra... Cingulate tDCS is safe and well-tolerated in PWH, and may have the potential to improve cognitive performance and brain function. A future study with a larger sample is warranted....

Noninvasive Brain Stimulation Techniques for Treatment-Resistant Depression: Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation.

Transcranial magnetic stimulation is a safe, effective, and well-tolerated intervention for depression; it is currently approved for treatment-resistant depression. This article summarizes the mechani...

Transcranial magnetic stimulation and transcranial direct current stimulation affect explicit but not implicit emotion regulation: a meta-analysis.

Emotion regulation (ER) refers to the process through which people influence the occurrence, experience, and expression of emotions. It can be established in an explicit (voluntary) or implicit (autom...

Novel ways to modulate the vestibular system: Magnetic vestibular stimulation, deep brain stimulation and transcranial magnetic stimulation / transcranial direct current stimulation.

Advances in neurotechnologies are revolutionizing our understanding of complex neural circuits and enabling new treatments for disorders of the human brain. In the vestibular system, electromagnetic s... In this narrative review, we describe evolving neuromodulatory techniques including magnetic vestibular stimulation (MVS), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), and tr... MVS triggers both vestibular nystagmic (persistent) and perceptual (lasting ∼1 min) responses that may serve as a model to study central adaptational mechanisms and pathomechanisms of hemispatial negl... Neuromodulation has a bright future as a potential treatment of vestibular dysfunction. MVS, DBS and TMS may provide new and sophisticated, customizable, and specific treatment options of vestibular s...

Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation as Treatment of Poststroke Depression: A Systematic Review and Meta-Analysis.

Previous studies showed that the application of repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) during stroke rehabilitation improve the depressi... Articles published before July 2021 were searched in databases: PubMed, Web of Science, and Google Scholar. STATA 12.0 software was utilized to make meta-analysis. We extracted or calculated mean valu... The study showed increased immediate and long-term improvement in depression in rTMS group compared with sham rTMS group after treatment with random-effects models (immediate: SMD=4.92, 95% CI=2.69-7.... rTMS and tDCS were demonstrated to be effective and safe treatment techniques for PSD. More large-scale studies were essential to explore the effect of rTMS with different frequencies and tDCS on PSD....

Transcranial Direct-Current Stimulation in Subacute Aphasia: A Randomized Controlled Trial.

Transcranial direct-current stimulation (tDCS) is a promising adjunct to therapy for chronic aphasia.... This single-center, randomized, double-blind, sham-controlled efficacy trial tested the hypothesis that anodal tDCS augments language therapy in subacute aphasia. Secondarily, we compared the effect o... Baseline characteristics were similar between the tDCS (N=30) and sham (N=28) groups: patients were 65 years old, 53% male, and 2 months from stroke onset on average. In intent-to-treat analysis, the ... tDCS did not improve recovery of picture naming but did improve recovery of discourse. Discourse skills are critical to participation. Future research should examine tDCS in a larger sample with riche... URL: https://www.... gov; Unique identifier: NCT02674490....

Transcranial direct current stimulation in stroke - Motor excitability and motor function.

To characterize motor excitability changes and changes of motor performance induced by a single anodal and cathodal transcranial direct current stimulation (tDCS) session in stroke patients.... Twenty subacute stroke patients participated. Motor performance was tested with the Box and Block Test [BBT]. Motor cortex excitability (short interval intracortical inhibition [SICI], intracortical f... Anodal tDCS significantly reduced SICI without changing ICF or LICI. Cathodal tDCS did not change motor excitability. Both types of tDCS did not alter motor performance. Even prior to anodal tDCS, SIC... Anodal, but not cathodal tDCS specifically modulated intracortical inhibitory circuits, leading to a disinhibition.... The results amplify our knowledge on excitability modulations of tDCS in stroke patients....